三诺生物全球研发中心封顶，预计年产值达30亿元

Core Insights - The construction of the Sanofi Global R&D Center in Changsha High-tech Zone has reached the final stages, with completion expected by the end of the year, marking the full establishment of the Sanofi Biotech Park [1] - The total investment for the third phase of the project is approximately 500 million yuan, focusing on the biosensor industry chain and aiming for a production value of 3 billion yuan annually upon completion [1][2] - Sanofi has established itself as a leader in the blood glucose monitoring system industry in China, holding over 50% market share domestically and exporting products to 187 countries [2] Investment and Economic Impact - The new R&D center will contribute over 200 million yuan in tax revenue and create nearly 2,000 new jobs [1] - The center will integrate software and hardware product development, talent training, testing, and result transformation, enhancing the company's capabilities in diabetes management [2] Company Background - Founded in 2002, Sanofi has become a high-tech enterprise specializing in the research and application of biosensor technology, successfully listed on the Shenzhen Stock Exchange in 2012 [2] - The company has established several national-level R&D platforms, including the National Enterprise Technology Center and the National Engineering Laboratory for Medical Big Data Application Technology [2]